ArticleFish physiology and biochemistry2025
Role of a non-steroidal aromatase inhibitor on growth performance, body composition, reproductive and serum biochemical indices, and intestinal histomorphology in hybrid red tilapia (Oreochromis spp.).
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-steroidal aromatase inhibitors like tamoxifen citrate are commonly used in aquaculture for sex reversal, yet their broader impacts on fish growth, body composition, serum biochemistry, and gut histomorphology remain underexplored. This study evaluated the effects of tamoxifen citrate on hybrid red tilapia fry growth, reproductive traits, haematological parameters, biochemical profiles, and reproductive hormone levels.A total of 260 swim-up fry (mean weight 0.06 ± 0.04 g) were randomly assigned to four dietary treatments: TA0 (0 mg/kg), TA1 (200 mg/kg), TA2 (400 mg/kg), and TA3 (600 mg/kg), with three replicates of 25 fish each. Fish were fed these diets for 60 days, followed by a 90-day recovery phase in outdoor hapas. The results showed that the male percentage increased significantly with tamoxifen inclusion, reaching 96.83% at 600 mg/kg (P < 0.05). Oestrogen levels decreased, while 11-ketotestosterone increased proportionally with tamoxifen dosage (P < 0.05). Higher tamoxifen inclusion (600 mg/kg) worsened feed conversion ratio (FCR), feed conversion efficiency (FCE), and protein efficiency ratio (PER) during the treatment phase but improved these parameters during recovery, alongside enhanced weight gain and specific growth rate (SGR) (P < 0.05). Higher tamoxifen doses increased hepatosomatic (HSI), viscerosomatic (VSI), and stomach indices while reducing gonadosomatic index (GSI) (P < 0.05). Elevated dosages reduced protein and lipid content but increased moisture levels (P < 0.05). Haemoglobin, MCV, MCH, and MCHC were higher at 200-400 mg tamoxifen/kg, while haematocrit declined with higher dosages (P < 0.05). Elevated tamoxifen levels increased AST, ALT, and globulin but decreased ALP, albumin, and cholesterol (P < 0.05). Moderate tamoxifen dosages (200-400 mg/kg) are recommended for sustainable sex reversal in hybrid red tilapia, minimising physiological and histological disruptions. High dosages (> 400 mg/kg) should be avoided due to haematological stress and immune suppression. Further studies are necessary to assess long-term ecological impacts and aquatic biodiversity.
Indexed as
Identifiers
39920535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.